Once the aims of a development program have been defined it is important to assess the drug development program options in terms of speed and risk, and where appropriate, consider novel approaches for more efficient drug development. This can include discussion of a range of design options to assess which is the best risk-managed option for your situation.
BENEFIT OF USING DANESTAT:
A wealth of experience in the design of drug development programs, working on studies in all phase of drug development (Phase 1 to Phase 4).
Experience reviewing such development programs as a member of a cross-functional Therapy Area governance committee
A track record in proposing, discussing and enacting novel approaches to drug development